<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01001130</url>
  </required_header>
  <id_info>
    <org_study_id>113596</org_study_id>
    <nct_id>NCT01001130</nct_id>
  </id_info>
  <brief_title>Regulatory AVAMYS Nasal Spray PMS</brief_title>
  <official_title>An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance (PMS) to Monitor the Safety and Effectiveness of Avamys® Administered in Korean Patients According to the Prescribing Information</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-interventional, open-label, single group, multicentric post-marketing surveillance to
      monitor the safety and effectiveness of AVAMYS nasal spray administered in Korean patients
      according to the prescribing information.

      AVAMYS is a registered trademark of the GSK group of companies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with an adverse event</measure>
    <time_frame>2 weeks</time_frame>
    <description>Number of participants with an adverse event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with a serious adverse event</measure>
    <time_frame>2 weeks</time_frame>
    <description>Number of participants with a serious adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with an unexpected or expected adverse drug reaction</measure>
    <time_frame>2 weeks</time_frame>
    <description>Number of participants with an unexpected or expected adverse drug reaction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness after AVAMYS nasal spray administration</measure>
    <time_frame>2 weeks</time_frame>
    <description>Effectiveness after AVAMYS nasal spray administration</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">3244</enrollment>
  <condition>Rhinitis, Allergic, Perennial and Seasonal</condition>
  <arm_group>
    <arm_group_label>fluticasone furoate group</arm_group_label>
    <description>Korean patients administered fluticasone furoate according to the Prescription information</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluticasone furoate group</intervention_name>
    <description>patients who are administered fluticasone furoate at least once</description>
    <arm_group_label>fluticasone furoate group</arm_group_label>
    <other_name>according to label and physician's decision</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients administrated AVAMYS nasal spray at the site
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        All subjects must satisfy the following criteria.

          1. Subject who is treated with AVAMYS nasal spray for the first time.

          2. Subject who is treated due to symptoms of seasonal and perennial allergic rhinitis in
             adults and children ≥2 years.

          3. Subject who is considered to follow the PMS protocol by an investigator.

          4. Subject who is contactable via telephone.

          5. Subject who is treated with AVAMYS nasal spray according to its prescribing
             information.

        As considering the characteristic of the observational post marketing surveillance, the
        exclusion criteria is not strict. All investigators should prescribe AVAMYS nasal spray
        according to prescribing information which approved in Korea.

        All subjects must not satisfy the following criteria.

          1. Subject who has hypersensitivity to its ingredients.

          2. As corticosteroids can slow the healing of wounds, if a subject who has surgery on
             his/her nose recently, or has a sore in his/her nose, or if his/her nose has been
             injured, the subject does not use AVAMYS nasal spray until his/her nose has healed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seongnam-si Gyeonggi-do</city>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2009</study_first_submitted>
  <study_first_submitted_qc>October 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2009</study_first_posted>
  <last_update_submitted>June 26, 2014</last_update_submitted>
  <last_update_submitted_qc>June 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>avamys</keyword>
  <keyword>Allergic Rhinitis</keyword>
  <keyword>post marketing surveillance</keyword>
  <keyword>Seasonal Allergic Rhinitis</keyword>
  <keyword>Perennial Allergic Rhinitis (PAR)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

